Related Experiment Videos

Cyclosporine A aggravates vascular endothelial injury in hyperlipidemic rats by down-regulating decay-accelerating

Wei Wang1, Peng Zhang, Jinjing Wang

  • 1Key Laboratory of Transplant Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu, PR China.

Biochemical and Biophysical Research Communications
|December 17, 2008
PubMed

Insights

Cyclosporine A (CsA) may increase vascular risk in hyperlipidemic patients by reducing decay-accelerating factor (DAF). This leads to complement-mediated endothelial cell lysis and damage.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Pharmacology

Background:

  • Cyclosporine A (CsA) is known to worsen vascular injury in hyperlipidemic patients.
  • The precise mechanisms underlying this exacerbation remain unclear.
  • Endothelial dysfunction is a key factor in cardiovascular disease progression.

Purpose of the Study:

  • To investigate the hypothesis that CsA induces complement-mediated endothelial cell lysis.
  • To explore the role of decay-accelerating factor (DAF) down-regulation in CsA-induced vascular injury.
  • To elucidate the mechanisms linking CsA, hyperlipidemia, and vascular risk.

Main Methods:

  • In vitro studies using human umbilical vein endothelial cells (HUVECs) treated with CsA and oxidized low-density lipoprotein (ox-LDL).
  • Flow cytometry was used to measure complement factor C3 binding to cells.
  • In vivo experiments utilized thoracic aortic endothelium from hyperlipidemic rats.

Main Results:

  • CsA exposure decreased DAF expression in HUVECs in a dose-dependent manner.
  • CsA aggravated ox-LDL-induced endothelial cell lysis.
  • In hyperlipidemic rats, CsA caused dose-dependent DAF down-regulation and endothelial damage.

Conclusions:

  • CsA down-regulates DAF expression, increasing susceptibility to complement-mediated endothelial cell lysis.
  • This mechanism contributes to the elevated vascular risk observed in hyperlipidemic patients treated with CsA.
  • Findings suggest a potential therapeutic target for mitigating CsA-associated vascular complications.

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...